Reference number(s)
2167-A

JURISDICTION SPECIFIC MEDICARE PART B

ENHERTU (fam-trastuzumab-deruxtecan-nxki)
HERCEPTIN (trastuzumab)
HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk)
HERZUMA (trastuzumab-pkrb)
KANJINTI (trastuzumab-anns)
OGIVRI (trastuzumab-dkst)
ONTRUZANT (trastuzumab-dttb)
PHESGO (pertuzumab/trastuzumab/hyaluronidase-zzxf)
TRAZIMERA (trastuzumab-qyyp)

POLICY

I. COVERED USES

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. Breast cancer
B. Metastatic gastric cancer
C. Metastatic gastroesophageal junction cancer

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available, upon request, for all submissions:
A. Medical records indicating the condition trastuzumab will be treating, staging, if applicable, prior therapy and the patient's response to that therapy
B. If the provider of the service is other than the referring/ordering physician, that provider must maintain copies of the ordering/referring physician's order for the chemotherapy drug

III. CRITERIA FOR APPROVAL

A. Breast cancer
Authorization of 12 months may be granted for treatment of breast cancer when any of the following criteria are met:

1. The member meets all of the following criteria:
   i. The member's disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for neoadjuvant/preoperative treatment
   iii. The disease is stage IIA, IIB, IIIA-C, or T3, N1, M0
   iv. Trastuzumab will be used in combination with paclitaxel followed by FEC/CEF (fluorouracil, epirubicin, and cyclophosphamide)

2. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for adjuvant treatment
   iii. The disease is stage I, IIA, IIB, IIIA-C, or T3, N1, M0
   iv. Trastuzumab will be used in combination with any of the following:
      a. Doxorubicin, cyclophosphamide, and paclitaxel
      b. Docetaxel and carboplatin
      c. As a single agent following multi-modality anthracycline-based therapy
      d. In combination with docetaxel followed by FEC/CEF (fluorouracil, epirubicin, and cyclophosphamide)
      e. Following chemotherapy
      f. In combination with docetaxel following doxorubicin and cyclophosphamide

3. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for advanced, recurrent, or metastatic disease
   iii. Trastuzumab will be used in combination with an aromatase inhibitor
   iv. The patient is postmenopausal or receiving concomitant suppression of testicular steroidogenesis
   v. The disease is estrogen-receptor positive
   vi. The patient has not received endocrine therapy within one year

4. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for advanced, recurrent, or metastatic disease
   iii. The member meets any of the following:
      a. Trastuzumab will be used in combination with paclitaxel for first line therapy
      b. Trastuzumab will be used as a single agent in patients who have received one or more chemotherapy regimens for metastatic disease
      c. Enhertu will be used as a single agent in patients who have received a prior anti-HER2-based regimen

5. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for advanced, recurrent, or metastatic disease
   iii. Trastuzumab will be used in combination with chemotherapy
   iv. The member must meet any of the below:
      a. Trastuzumab will be used in combination with docetaxel, vinorelbine, or capecitabine for first line therapy or with paclitaxel with or without carboplatin
      b. The patient has been previously treated with trastuzumab for breast cancer in combination with lapatinib without cytotoxic therapy, with docetaxel, vinorelbine, or capecitabine, or with paclitaxel with or without carboplatin
   v. The disease is hormone receptor-negative or hormone receptor-positive and endocrine refractory

vi. The disease is not characterized by having bone or soft-tissue involvement only or asymptomatic visceral disease

6. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for metastatic disease
   iii. Trastuzumab will be used in combination with pertuzumab and docetaxel or the requested product is Phesgo
   iv. The member has not received prior anti-HER2 therapy or chemotherapy for metastatic disease

7. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used for locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)
   iii. Trastuzumab will be used in combination with pertuzumab and chemotherapy or the requested product is Phesgo
   iv. Trastuzumab will be used for neoadjuvant treatment
   v. Trastuzumab will be used as part of a complete treatment regimen for early breast cancer

8. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. Trastuzumab will be used in combination with pertuzumab and chemotherapy or the requested product is Phesgo
   iii. Trastuzumab will be used for adjuvant treatment of early breast cancer at high risk of recurrence

B. Gastric or gastroesophageal junction cancer
Authorization of 12 months may be granted for treatment of gastric cancer when any of the following criteria are met:

1. The member meets all of the following criteria:
   i. The requested product is Enhertu
   ii. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   iii. The disease is locally advanced or metastatic
   iv. The patient has received a prior trastuzumab-based regimen

2. The member meets all of the following criteria:
   i. The disease is human epidermal growth factor receptor 2 (HER2)-positive
   ii. The disease is metastatic
   iii. The patient has not received prior treatment for metastatic disease
   iv. Trastuzumab will be used in combination with any of the following:
      a. 5-fluorouracil
      b. Cisplatin and capecitabine

IV. REFERENCES

1. Trastuzumab – Trastuzumab Biologics LCD (L34026) Version R3. Available at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34026&ver=16&Date=01%2f14%2f2020&DocID=L34026&SearchType=Advanced&bc=KAAAABAAAAAA& Accessed December 20, 2021.

2. Trastuzumab – Trastuzumab Biologics LCA (A56660) Version R7. Available at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34026&ver=16&Date=01%2f14%2f2020&DocID=L34026&SearchType=Advanced&bc=KAAAABAAAAAA& Accessed December 20, 2021.
3. Perjeta [package insert]. South San Francisco, CA: Genentech, Inc.; February 2021.
4. Phesgo [package insert]. South San Francisco, CA: Genentech, Inc.; June 2020.
5. Enhertu [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; May 2022.